In addition to the high concentration of total tau (T-tau) and P-tau, the reduced levels of Aβ1-42 represent the third core CSF biomarkers for AD [71], whereas the ability to discriminate AD from non-AD patients based on the blood levels of Aβ1-42 remains unclear [72]. Here, MAPT is linked to Alzheimer disease.